Interim report from Medivir

Medivir (STO:MVIRB)

• Consolidated net sales were SEK 24.5 (31.9) m.
• The loss after tax was SEK -93.0 (-102.4) m.
• Earnings per share were SEK -4.46 (-4.91).
• Cash flow from operating activities was SEK -104.8 (-30.4) m.
• Liquid assets and short-term investments as of 30 September were SEK 176.1 (295.7) m.

Third quarter in brief

Several significant project events were reported in the quarter.

The highlights can be summarized as follows:

• FDA approved Lipsovir® with a competitive label for marketing and sales in the US.

• At present, two phase IIb trials involving a total of 855 patients are ongoing on TMC435 against hepatitis C. The latter of these trials (C-206) started in September and involves 455 patients that previously did not respond to standard of care (SoC).

• Medivir designated another candidate drug (CD), MIV-711 in its osteoporosis portfolio, thus enhancing its commercial opportunities.

Ron Long
CEO

Huddinge, Sweden, 21 October 2009

FORTHCOMING FINANCIAL INFORMATION

The Financial Statement for 12 months will be published on 18 February 2010.
The Three-month Interim Report will be published on 29 April 2010.
The Annual General Meeting (AGM) will be held on 29 April 2010.

The Reports will be available at Medivir’s Website, www.medivir.se from this date under the ‘Investor/Media’ heading.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.